By the time you read this, the recaps will already look identical. The Supreme Court ruled 7 to 2 for Monsanto. FIFRA preempts failure-to-warn claims. Tens of thousands of Roundup cases are in jeopardy. Bayer’s stock moved. Every outlet from the wire services to...
The “Shield” Is Gone For years, the Johnson & Johnson talc lawsuit was defined by a single stalling tactic: the “Texas Two-Step” bankruptcy maneuver. That era is officially over. The rejection of J&J’s third bankruptcy attempt in early...
The State of the Docket: Is There Still Opportunity? After years of massive, high-profile settlements—with Bayer allocating billions of dollars to resolve roughly 100,000 claims—many law firms assume the Roundup litigation is finally winding down. Here’s the reality:...
The New Mass Tort Challenge: Sensitivity Meets Scale The Hair Relaxer litigation—centered on allegations that chemicals like endocrine-disrupting chemicals (EDCs) found in common products are linked to serious hormone-sensitive cancers—is one of the fastest-growing...
The Cost of Low Quality: Why Bad Leads are Worse Than No Leads The acquisition of mass tort leads is now more competitive and expensive than ever. As the Estimated CPL (Cost Per Lead) for emerging dockets climbs, chasing volume over mass tort lead quality is the...
The New Mass Tort Economics: Why Case Quality is the Only Metric that Matters For law firms focused on mass torts, 2025 is less about chasing volume and more about securing verified case quality. As the cost of acquisition rises and regulatory scrutiny...
